Piramal Pharma Solutions has agreed to acquire the solid oral dosage drug product manufacturing facility of G&W Laboratories in Sellersville, Pennsylvania for an undisclosed price.

A subsidiary of India-based conglomerate Piramal Enterprises, the company is a contract development and manufacturing organization (CDMO), which provides end-to-end development and manufacturing solutions across the drug life cycle.

According to Piramal Enterprises, the acquisition broadens the offering of its CDMO subsidiary by adding solid oral dosage form capabilities in North America. So far, the capabilities of Piramal Pharma Solutions in solid oral dosage forms were all pertained to the UK and India.

The Sellersville solid oral dosage drug product manufacturing facility can also manufacture liquids, ointments, and creams, thereby growing the portfolio of Piramal Pharma Solutions.

The plant, which has certifications from FDA and EMA, can also support product and process development for solid oral dosage and oral liquids, which include immediate release, modified release, chewable and sublingual solid oral dosage forms, solutions and suspensions in liquids.

Peter DeYoung – CEO of Piramal Pharma Solutions said: “Many of our customers are looking for US-based manufacturing partners to expand and support their pipeline. This acquisition strengthens our ability to partner with them on best-in-class drug products. It enhances our market-leading integrated services offering by adding a solid oral dosage capability in the US.

“We now offer solid oral drug product development and commercial manufacturing in all our major geographies, addressing a previously unmet customer need and strengthening our ability to work globally with customers to reduce the burden of disease on patients.”

  CDMO, G&W Laboratories, Pennsylvania, Peter DeYoung, Piramal Enterprises, Piramal Pharma Solutions, Sellersville, USA